RTX-240 Investigational New Drug Application for Solid Tumors Cleared by U.S. FDA
Internal cGMP Manufacturing Ready to Support Upcoming Oncology Clinical Trials
Cash Runway Extended into 2022
Conference Call Scheduled for Today at 8:00 a.m. EST
CAMBRIDGE, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY) a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today reported fourth quarter and full-year 2019 financial results and announced its plan to focus on the development of its oncology and autoimmunity pipeline.
This strategic decision allows Rubius to focus on the areas in which its RED PLATFORM® may offer the greatest potential to benefit patients. Development in these therapeutic areas is enabled by the Company’s investment in internal manufacturing at its Smithfield, RI facility, which is now cGMP ready to produce clinical supply for its lead oncology program, RTX-240, a broad immunostimulatory Red Cell Therapeutic™ for the treatment of solid tumors. The Investigational New Drug (IND) application for RTX-240 has been cleared by the U.S. Food and Drug Administration, and the Company plans to announce when the first patient has been dosed in the Phase 1 clinical trial. As previously announced, Rubius is on track to file an IND for RTX-321, its first artificial antigen-presenting cell for the treatment of HPV-positive cancers, by year-end. The company also expects to manufacture RTX-321 clinical supply at its fully owned manufacturing facility.
“Over the past two years, we have generated exciting oncology preclinical data, demonstrating the ability of our Red Cell Therapeutics to both broadly activate the immune system, and induce tumor-specific responses by activating and expanding antigen-specific T cells with our artificial antigen-presenting cells. By focusing on the development of our oncology and autoimmune pipeline, we believe we will have the greatest opportunity to bring life-saving therapies to patients, enhance shareholder value and extend our cash runway into 2022,” said Pablo J. Cagnoni, M.D., president and chief executive officer of Rubius Therapeutics. “With our internal cGMP manufacturing established, we are well positioned to advance this entirely new class of allogeneic cellular medicines.”
RTX-240 for the Treatment of Solid Tumors
RTX-240 is an allogeneic cellular therapy that is engineered to broadly stimulate the adaptive and innate immune systems to generate an antitumor response. RTX-240 expresses 4-1BBL and IL-15TP, a fusion of IL-15 and IL-15 receptor alpha, on the cell surface with the goal of improving antitumor activity and overcoming resistance to immunotherapy in patients with solid tumors. RTX-240 may provide a differentiated approach to treating solid tumors or hematologic malignancies in immunotherapy-naïve patients or in patients whose disease has become resistant or refractory to immunotherapies, including checkpoint inhibitors.
RTX-134 Program Update
As a result of the decision to focus on oncology and autoimmunity, the Company is deprioritizing the RTX-134 program for the treatment of phenylketonuria (PKU) and its other rare disease programs. Multiple factors contributed to this decision, including unanticipated delays in the RTX-134 program, primarily due to continued manufacturing challenges at the Company’s contract manufacturing organization (CMO), the anticipated high cost associated with producing chronic, high-dose therapy for enzyme deficiencies and the continued momentum of the Company’s oncology pipeline. Future capital investments and improvements in manufacturing efficiency, together with enhancements to the RED PLATFORM, may enable Rubius to revisit chronic, high dose-dependent conditions in the future.
As previously announced, the first patient was dosed in the Phase 1b PKU clinical trial of RTX-134 in January 2020. While there were no reported adverse events and RTX-134 administration was well tolerated, the results from the first patient were uninterpretable possibly due, in part, to the low dose of cells administered and the sensitivity of the flow cytometry assay used to detect circulating cells. As a result of the deprioritization, the current Phase 1b clinical trial in PKU will be discontinued.
Autoimmune Program Update
Rubius’ autoimmune Red Cell Therapeutics are engineered to express specific autoimmune disease-associated antigens either within the cell or on the cell surface to take advantage of how the body normally maintains self-tolerance, thereby retraining the immune system to no longer see self-antigens as foreign. Red Cell Therapeutics are designed to specifically modulate complex counter‑regulatory immune responses, potentially enabling greater efficacy with lower toxicity, and, in some cases, even cures, when compared to currently available non-specific immunosuppressive treatments. Rubius is focusing on T cell-mediated autoimmune diseases and is pursuing Type 1 diabetes, along with a number of other undisclosed programs. The Company expects to provide an update on its preclinical autoimmune pipeline in the future.
Extension of Cash Runway
With the cost savings from the discontinuation of the RTX-134 clinical trial and deprioritization of the other rare disease programs and a reallocation of capital and personnel resources, Rubius’ cash runway will be extended into 2022.
Additional Business Updates
Rubius strengthened its leadership team and board of directors by appointing:
Fourth Quarter 2019 Financial Results
Net loss for the fourth quarter of 2019 was $44.5 million or $0.56 per common share, compared to $27.2 million or $0.35 per common share in the fourth quarter of 2018.
In the fourth quarter of 2019, Rubius invested $30.5 million in research and development (R&D) related to its novel RED PLATFORM and towards expanding and advancing its product pipeline, as compared to $16.5 million in the fourth quarter of 2018. This year-over-year increase was driven primarily by $3.9 million in incremental R&D program spending related to the Company’s Phase 1b clinical trial for RTX-134 and towards preclinical and IND-enabling activities for Rubius’ lead oncology programs, including RTX-240. In addition, $6.0 million in incremental R&D spending was driven by increased R&D headcount, a move into larger facilities and purchasing lab supplies to support expanded research activities. Contract research and development costs increased by $3.3 million and R&D stock-based compensation also increased by $0.8 million.
G&A expenses were $14.9 million during the fourth quarter of 2019, as compared to $12.6 million for the fourth quarter of 2018. The higher costs were primarily driven by a $1.0 million increase in personnel and facility costs due to increased headcount in the general and administrative function, as well as increases in professional fees and infrastructure costs to support the Company’s growth.
Full Year 2019 Financial Results
Net loss for the full year 2019 was $163.5 million or $2.08 per common share, compared to $89.2 million or $2.27 per common share for the full year 2018.
For the full year 2019, Rubius invested $112.4 million in R&D related to its novel RED PLATFORM and towards expanding and advancing its product pipeline, compared to $51.8 million for the full year 2018. This year-over-year increase was largely due to an additional $31.8 million in R&D personnel, contract research and development, facilities and lab supplies to support the Company’s pipeline expansion and platform investments and $23.7 million in R&D program spending, including costs related to the Company’s RTX-134 Phase 1b clinical trial as well as preclinical and IND-enabling activities for Rubius’ lead oncology programs, including RTX-240. R&D stock-based compensation also increased by $5.2 million.
G&A expenses were $57.2 million during the twelve months of 2019, as compared to $39.9 million for the same period in 2018. The higher costs were primarily driven by an $8.5 million increase in stock-based compensation and $8.8 million increase in personnel costs, professional and facility fees to support the Company’s growth and to operate as a public company.
As of December 31, 2019, cash, cash equivalents and investments were $283.3 million as compared to $404.1 million as of December 31, 2018, providing Rubius with a cash runway into 2022. During the year, the Company used $110.4 million of cash to fund operations and $40.7 million to fund capital expenditures, including work related to the buildout of Rubius’ manufacturing facility. In addition, the Company drew down a second tranche of $25.0 million from its $75.0 million loan agreement with Solar Capital in June 2019, which leaves a third tranche of $25.0 million that can be drawn through June 2020, subject to the satisfaction of certain financial covenants.
Conference Call Details
The company will host a conference call and webcast at 8:00 a.m. EST to discuss this update. The audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website. The update may also be accessed by dialing 1-800-289-0045 (domestic) or 1-615-622-8086 (international) five minutes prior to the start of the call and providing the passcode 6394385. An archived webcast will be accessible for 90 days after the event.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the planned timing, enrollment and results for our preclinical and clinical activities, including the Phase 1 clinical trial for RTX-240, our ability to fund the further development of our Red Cell Therapeutic product candidates, statements regarding the operation of our manufacturing facility and availability of supply for our clinical trials, our expectations regarding the therapeutic potential of our Red Cell Therapeutics, including RTX-240 for the treatment of solid tumors, the timelines for us to file additional INDs, and our strategy, business plans and focus, including the benefits we expect from our recent strategic shift to focus on the development of our oncology and autoimmunity pipeline. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the development of our Red Cell Therapeutic product candidates and their therapeutic potential and other risks identified in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.
Rubius Therapeutics, Inc.
Condensed Consolidated Statement of Operations
(in thousands, except share and per share data)
|For the three months ended|
|For the year ended |
|Research and development||30,500||16,539||112,419||51,769|
|General and administrative||14,928||12,583||57,182||39,894|
|Total operating expenses||45,428||29,122||169,601||91,663|
|Loss from operations||(45,428||)||(29,122||)||(169,601||)||(91,663||)|
|Other income (expense), net||956||1,939||6,143||2,468|
|Net loss per share, basic and diluted||$||(0.56||)||$||(0.35||)||$||(2.08||)||$||(2.27||)|
|Weighted average common shares outstanding, basic and diluted:||79,671,342||76,747,827||78,688,878||39,285,468|
Rubius Therapeutics, Inc.
Condensed Consolidated Balance Sheet Data
|December 31,||December 31,|
|Cash, cash equivalents and investments||$||283,287||$||404,051|
|Total stockholders' equity||274,213||393,008|